VERU

Veru Inc. [VERU] Stock Forecast

Q: What is Veru Inc. stock symbol ?

Veru Inc. is a US stock, located in Miami of Fl and trading under the symbol VERU

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

VERU Stock Summary

VERU has more than 6 years of cash runway (77 months)

Earnings are expected to fall -100% next year

EPS has been decreasing for the past 3 years (Yearly statements)

Top 10 Correlated ETFs

VERU

Top 10 Correlated Stocks

VERU

In the News

VERU Financial details

Company Rating

Sell

Market Cap

222.5M

Income

-64.52M

Revenue

15.93M

Book val./share

0.51

Cash/share

0.4

Dividend

Dividend %

Employees

189

Optionable

Shortable

Yes

Earnings

09 May 2024

P/E

-0.5

Forward P/E

PEG

0.18

P/S

4.81

P/B

2.63

P/C

3.55

P/FCF

-0.88

Quick Ratio

0.7

Current Ratio

1.16

Debt / Equity

0.21

LT Debt / Equity

0.17

EPS (TTM)

-0.75

EPS next Y

EPS next Q

EPS this Y

4.76%

EPS next Y

EPS next 5Y

EPS last 5Y

42.08%

Revenue last 5Y

-12.52%

Revenue Q/Q

-44.57%

EPS Q/Q

-68.35%

SMA20

125%

SMA50

187.23%

SMA100

35%

Inst Own

13.17%

Inst Trans

0.68%

ROA

-184%

ROE

-316%

ROC

-2.96%

Gross Margin

46%

Oper. Margin

-551%

Profit Margin

-571%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

0.36-1.92

52W High

52W Low

RSI

64.07

Rel Volume

3.16

Avg Volume

2.21M

Volume

6.99M

Perf Week

21.37%

Perf Month

121.18%

Perf Quarter

66.16%

Perf Half Y

42%

Beta

-0.197

Volatility

0.2%, 0.35%

Prev Close

22.41%

Price

1.42

Change

13.6%

VERU Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-09-30

Metric	2019-09-30	2020-09-30	2021-09-30	2022-09-30	2023-09-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.5	0.64	0.8	0.49	0.19
Net income per share	-0.19	-0.28	0.1	-1.05	-1.1
Operating cash flow per share	-0.09	-0.03	-0.2	-0.59	-1.04
Free cash flow per share	-0.09	-0.03	-0.21	-0.6	-1.04
Cash per share	0.1	0.2	1.6	1	0.11
Book value per share	0.51	0.45	2	1.01	0.21
Tangible book value per share	0.08	0.26	1.85	0.87	0.13
Share holders equity per share	0.51	0.45	2	1.01	0.21
Interest debt per share	0.27	0.28	0.23	0.24	0.2
Market cap	136.78M	174.89M	650.61M	923.01M	61.1M
Enterprise value	142.6M	175.44M	540.88M	857.74M	65.88M
P/E ratio	-11.38	-9.22	87.99	-11.02	-0.66
Price to sales ratio	4.3	4.11	10.62	23.45	3.75
POCF ratio	-24.94	-90.61	-41.78	-19.43	-0.69
PFCF ratio	-24.45	-85.91	-40.8	-19.13	-0.69
P/B Ratio	4.23	5.81	4.27	11.42	3.44
PTB ratio	4.23	5.81	4.27	11.42	3.44
EV to sales	4.48	4.12	8.83	21.8	4.04
Enterprise value over EBITDA	-22.16	-11.9	-22.68	-10.31	-0.7
EV to operating cash flow	-26	-90.9	-34.74	-18.06	-0.75
EV to free cash flow	-25.49	-86.18	-33.92	-17.78	-0.74
Earnings yield	-0.09	-0.11	0.01	-0.09	-1.52
Free cash flow yield	-0.04	-0.01	-0.02	-0.05	-1.45
Debt to equity	0.37	0.47	0.08	0.18	0.81
Debt to assets	0.23	0.27	0.07	0.11	0.28
Net debt to EBITDA	-0.9	-0.04	4.6	0.78	-0.05
Current ratio	1.2	1.83	9.62	2.53	1.16
Interest coverage	-1.37	-3.19	-1.12	-19.05	-38.61
Income quality	0.46	0.1	-2.11	0.57	0.95
Dividend Yield	0	0.08	0	0	0
Payout ratio	0	-0.73	0	0	0
Sales general and administrative to revenue	0.45	0.34	0.34	1.1	2.95
Research and developement to revenue	0.43	0.4	0.53	1.8	3.14
Intangibles to total assets	0.5	0.25	0.06	0.08	0.14
Capex to operating cash flow	0.02	0.05	0.02	0.02	0.01
Capex to revenue	0	0	-0.01	-0.02	-0.04
Capex to depreciation	-0.23	-0.23	-1.78	-3.5	-2.47
Stock based compensation to revenue	0.06	0.06	0.08	0.29	1.1
Graham number	1.48	1.7	2.09	4.87	2.27
ROIC	-0.14	-0.3	-0.06	-0.84	-2.56
Return on tangible assets	-0.45	-0.49	0.04	-0.67	-2.13
Graham Net	-0.15	-0.01	1.39	0.4	-0.19
Working capital	2.79M	12.29M	135.99M	63.33M	3.23M
Tangible asset value	5.29M	17.48M	141.37M	69.98M	10.9M
Net current asset value	-4.49M	5.58M	125.9M	49.48M	-9.31M
Invested capital	0.37	0.47	0.08	0.18	0.81
Average receivables	4.5M	5.12M	7.01M	6.17M	4.03M
Average payables	3.18M	2.97M	3.11M	12.71M	18.29M
Average inventory	2.97M	5.18M	6.14M	7.1M	7.66M
Days sales outstanding	57.63	44.8	52.4	32.93	100.93
Days payables outstanding	112.41	86.96	93.35	916.5	609.37
Days of inventory on hand	131.21	207.28	152.61	359	279.97
Receivables turnover	6.33	8.15	6.97	11.08	3.62
Payables turnover	3.25	4.2	3.91	0.4	0.6
Inventory turnover	2.78	1.76	2.39	1.02	1.3
ROE	-0.37	-0.63	0.05	-1.04	-5.23
Capex per share	0	0	0	-0.01	-0.01

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q1

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.03	0.08	0.04	0.04	0.02
Net income per share	-0.46	-0.48	0.07	-0.26	-0.08
Operating cash flow per share	-0.43	-0.32	-0.21	-0.1	-0.06
Free cash flow per share	-0.43	-0.32	-0.21	-0.11	-0.06
Cash per share	0.58	0.29	0.18	0.1	0.4
Book value per share	0.61	0.21	0.39	0.19	0.51
Tangible book value per share	0.47	0.12	0.31	0.12	0.44
Share holders equity per share	0.61	0.21	0.39	0.19	0.51
Interest debt per share	0.21	0.2	0.18	0.16	0.11
Market cap	425.35M	93.77M	105.04M	65.99M	72.43M
Enterprise value	394.63M	85.87M	104.02M	70.77M	46.06M
P/E ratio	-2.89	-0.6	4.16	-0.69	-2.19
Price to sales ratio	169.61	14.24	31.44	17.09	33.84
POCF ratio	-12.32	-3.67	-5.7	-6.95	-12.03
PFCF ratio	-12.22	-3.65	-5.69	-6.8	-12.03
P/B Ratio	8.66	5.61	3.05	3.71	1.4
PTB ratio	8.66	5.61	3.05	3.71	1.4
EV to sales	157.36	13.04	31.13	18.33	21.52
Enterprise value over EBITDA	-11.09	-2.72	-8.56	-5.98	-5.28
EV to operating cash flow	-11.43	-3.36	-5.64	-7.46	-7.65
EV to free cash flow	-11.33	-3.34	-5.64	-7.29	-7.65
Earnings yield	-0.09	-0.41	0.06	-0.36	-0.11
Free cash flow yield	-0.08	-0.27	-0.18	-0.15	-0.08
Debt to equity	0.33	0.93	0.44	0.81	0.21
Debt to assets	0.16	0.22	0.2	0.28	0.13
Net debt to EBITDA	0.86	0.25	0.08	-0.4	3.02
Current ratio	1.82	1.1	1.56	1.16	3.21
Interest coverage	-40.75	-50.91	7.49	-113.76	-53.35
Income quality	0.94	0.66	-2.92	0.4	0.73
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	1.95	0	0	0
Research and developement to revenue	7.47	3.47	0.88	1.71	0.77
Intangibles to total assets	0.1	0.1	0.09	0.14	0.09
Capex to operating cash flow	0.01	0.01	0	0.02	0
Capex to revenue	-0.11	-0.02	-0.01	-0.06	0
Capex to depreciation	-4.52	-2.16	-0.36	-3.03	0
Stock based compensation to revenue	1.93	0.58	1.36	1.21	1.59
Graham number	2.5	1.49	0.79	1.06	0.97
ROIC	-0.51	-0.98	0.09	-0.65	-0.13
Return on tangible assets	-0.4	-0.61	0.09	-0.54	-0.11
Graham Net	-0.01	-0.29	-0.13	-0.18	0.17
Working capital	32.93M	4.03M	15.53M	3.23M	36.72M
Tangible asset value	38.26M	9.8M	27.48M	10.9M	44.72M
Net current asset value	18.33M	-10.25M	2.41M	-9.31M	24.38M
Invested capital	0.33	0.93	0.44	0.81	0.21
Average receivables	3.71M	4.04M	8.91M	9.06M	3.44M
Average payables	16.29M	13.9M	17.68M	16.35M	12.55M
Average inventory	8.68M	8.2M	7.08M	6.59M	6.8M
Days sales outstanding	138.68	57.48	366.86	105.02	100.18
Days payables outstanding	526.67	622.07	772.62	565.27	955.95
Days of inventory on hand	435.24	276.62	276.75	259.71	628.21
Receivables turnover	0.65	1.57	0.25	0.86	0.9
Payables turnover	0.17	0.14	0.12	0.16	0.09
Inventory turnover	0.21	0.33	0.33	0.35	0.14
ROE	-0.75	-2.32	0.18	-1.34	-0.16
Capex per share	0	0	0	0	0

VERU Frequently Asked Questions

What is Veru Inc. stock symbol ?

Veru Inc. is a US stock , located in Miami of Fl and trading under the symbol VERU

What is Veru Inc. stock quote today ?

Veru Inc. stock price is $1.42 today.

Is Veru Inc. stock public?

Yes, Veru Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 2.21M
Market Capitalization 222.5M
Employee 189
CEO Dr. Mitchell S. Steiner F.A.C.S., M.D.
Headquarters Miami,FL,US
IPO Date 1999-02-11
Website https://www.verupharma.com

Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.